Market Overview

Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest Cash

Related ILMN
US Stock Futures Surge Ahead Of Economic Data
Markets Mostly Higher Despite Initial Negative Reaction From FOMC Minutes

Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of cash.

Illumina (NASDAQ: ILMN) had $1.27 billion in total cash and $815.97 million in total debt for the latest quarter.

Onyx Pharmaceuticals (NASDAQ: ONXX) had $599.99 million in total cash and $165.64 million in total debt for the latest quarter.

Human Genome Sciences (NASDAQ: HGSI) had $471.80 million in total cash and $821.50 million in total debt for the latest quarter.

VIVUS (NASDAQ: VVUS) had $333.40 million in total cash and no debt for the latest quarter.

Posted-In: Biotechnology Industry highest cash Mid-CapTrading Ideas

 

Related Articles (HGSI + ILMN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters